Search Results - "Kalbakis, K."

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study by Georgoulias, V., Bozionelou, V., Agelaki, S., Perraki, M., Apostolaki, S., Kallergi, G., Kalbakis, K., Xyrafas, A., Mavroudis, D.

“…Since the detection of circulating tumor cells (CTCs) which express HER2 is an adverse prognostic factor in early breast cancer patients, we investigated the…”
Get full text

Correlation of various clinical, imaging and laboratory parameters with outcome in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs): Results from a prospective, observational, single institution study by Rounis, K., Papadaki, C., Makrakis, D., Monastirioti, A., Vamvakas, L., Kalbakis, K., Mavroudis, D., Aggelaki, S.

Get full text

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial by Saridaki, Z, Androulakis, N, Vardakis, N, Vamvakas, L, Kabouraki, E, Kalbakis, K, Hatzidaki, D, Voutsina, A, Mavroudis, D, Georgoulias, V, Souglakos, J

“…Background: We conducted an open-label, pilot phase II trial to evaluate the efficacy and safety of FOLFOXIRI plus cetuximab as first-line treatment of…”
Get full text

Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) by Katopodis, O., Souglakos, J., Stathopoulos, E., Christopoulou, A., Kontopodis, E., Kotsakis, A., Kalbakis, K., Kentepozidis, N., Polyzos, A., Hatzidaki, D., Georgoulias, V.

“…Purpose Intravenous gemcitabine is the standard of care for patients with metastatic cancer of the pancreas. Gemcitabine-based chemotherapy combinations,…”
Get full text

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer by Androulakis, N, Agelaki, S, Perraki, M, Apostolaki, S, Bozionelou, V, Pallis, A, Kalbakis, K, Xyrafas, A, Mavroudis, D, Georgoulias, V

“…Background: To investigate the clinical relevance of CK-19mRNA-positive circulating tumour cells (CTCs) detected before the initiation of front-line treatment…”
Get full text

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer by Xenidis, N, Perraki, M, Apostolaki, S, Agelaki, S, Kalbakis, K, Vardakis, N, Kalykaki, A, Xyrafas, A, Kakolyris, S, Mavroudis, D, Georgoulias, V

“…Background: To determine the effect of adjuvant taxane-free and taxane-based chemotherapy regimens on the elimination of circulating tumour cells (CTCs) in…”
Get full text

Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG) by Kotsakis, A, Kentepozidis, N, Emmanouilidis, Ch, Polyzos, A, Agelidou, A, Vaslamatzis, M, Chandrinos, V, Agelaki, S, Vamvakas, L, Kalbakis, K, Katsaounis, P, Stoltidis, D, Nintos, G, Hatzidaki, D, Vetsika, E.K, Mavroudis, D, Georgoulias, V

“…Highlights • Platinum-based chemotherapy is considered the cornerstone of treatment for NSCLC. • Bevacizumab with sequential chemotherapy is feasible with…”
Get full text

Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance by Apostolaki, S, Perraki, M, Pallis, A, Bozionelou, V, Agelaki, S, Kanellou, P, Kotsakis, A, Politaki, E, Kalbakis, K, Kalykaki, A, Vamvakas, L, Georgoulias, V, Mavroudis, D

“…Background: The purpose of this study was to evaluate the prognostic value of circulating tumor cells (CTCs) expressing HER2 messenger RNA (mRNA) after the…”
Get full text

Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer by Kontopodis, E., Kentepozidis, N., Christophyllakis, Ch, Boukovinas, I., Kalykaki, A., Kalbakis, K., Vamvakas, L., Agelaki, S., Kotsakis, A., Vardakis, N., Georgoulias, V., Mavroudis, D.

“…Purpose To evaluate the activity and safety of the docetaxel, gemcitabine and bevacizumab combination, administered biweekly, in pretreated patients with…”
Get full text

Triplet Combination With Irinotecan Plus Oxaliplatin Plus Continuous-Infusion Fluorouracil and Leucovorin as First-Line Treatment in Metastatic Colorectal Cancer: A Multicenter Phase II Trial by SOUGLAKOS, J, MAVROUDIS, D, SAMONIS, G, GEORGOULIAS, V, KAKOLYRIS, S, KOUROUSIS, Ch, VARDAKIS, N, ANDROULAKIS, N, AGELAKI, S, KALBAKIS, K, TSETIS, D, ATHANASIADIS, N

“…To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont…”
Get full text

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG) by Kentepozidis, N., Economopoulou, P., Christofyllakis, Ch, Chelis, L., Polyzos, A., Vardakis, N., Koinis, F., Vamvakas, L., Katsaounis, P., Kalbakis, K., Nikolaou, Ch, Georgoulias, V., Kotsakis, A.

“…Background Platinum-based chemotherapy is the standard front-line treatment for patients with advanced non-small cell lung cancer (NSCLC). However,…”
Get full text

Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer by Georgoulias, V., Apostolaki, S., Bozionelou, V., Politaki, E., Perraki, M., Georgoulia, N., Kalbakis, K., Kotsakis, A., Xyrafas, A., Agelaki, S., Mavroudis, D.

“…Purpose To evaluate the effect of front-line chemotherapy on CK-19mRNA+ circulating tumor cells (CTCs) and their relevance in patients with metastatic breast…”
Get full text

Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG) by Vamvakas, L, Athanasiadis, A, Karampeazis, A, Kakolyris, S, Polyzos, A, Kouroussis, Ch, Ziras, N, Kalbakis, K, Georgoulias, V, Souglakos, J

“…Abstract Background A subgroup analysis of oxaliplatin (LOHP) + irinotecan (CPT-11) + 5-fluorouracil (5FU) and leucovorin (LV) (FOLFOXIRI regimen) versus…”
Get full text

Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy by Souglakos, J., Kalykaki, A., Vamvakas, L., Androulakis, N., Kalbakis, K., Agelaki, S., Vardakis, N., Tzardi, M., Kotsakis, A.P., Gioulbasanis, J., Tsetis, D., Sfakiotaki, G., Chatzidaki, D., Mavroudis, D., Georgoulias, V.

“…Background: Cetuximab is an IgG1 monoclonal antibody targeting the epidermal growth factor receptor and is able to reverse the resistance to irinotecan in…”
Get full text

A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer by Agelaki, S., Kontopodis, E., Kotsakis, A., Chandrinos, V., Bompolaki, I., Zafeiriou, Ζ., Papadimitraki, E., Stoltidis, D., Kalbakis, K., Georgoulias, V.

“…Purpose To determine the dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of oral topotecan administered weekly in patients with relapsed…”
Get full text

A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer by Karachaliou, N., Kouroussis, Ch, Papakotoulas, P., Kalbakis, K., Tryfonidis, K., Vardakis, N., Poppis, E., Georgoulias, V., Mavroudis, D.

“…Objective To evaluate the docetaxel–gemcitabine (DG) combination administered every 2 weeks as salvage therapy in anthracycline- and taxane-pretreated patients…”
Get full text

Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine : a multicenter randomised phase II study by GEORGOULIAS, V, AGELIDOU, A, KALBAKIS, K, SAMONIS, G, MAVROUDIS, D, SYRIGOS, K, RAPTI, A, AGELIDOU, M, NIKOLAKOPOULOS, J, POLYZOS, A, ATHANASIADIS, A, TSELEPATIOTIS, E, ANDROULAKIS, N

“…The aim of this study was to compare the irinotecan/cisplatin regimen with cisplatin as second-line chemotherapy in patients with advanced non-small-cell lung…”
Get full text

First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study by Papakostas, P, Kouroussis, Ch, Androulakis, N, Samelis, G, Aravantinos, G, Kalbakis, K, Sarra, E, Souglakos, J, Kakolyris, S, Georgoulias, V

“…The purpose was to evaluate the efficacy and safety profile of docetaxel as first-line chemotherapy for patients with locally advanced or metastatic biliary…”
Get full text

Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: A multicenter phase II study by Boukovinas, I, Souglakos, J, Hatzidaki, D, Kakolyris, S, Ziras, N, Vamvakas, L, Polyzos, A, Geroyianni, A, Agelidou, A, Agelaki, S, Kalbakis, K, Kotsakis, A, Mavroudis, D, Georgoulias, V

“…Summary Background The docetaxel/gemcitabine (DG) combination is an active and well-tolerated regimen against non-small cell lung cancer (NSCLC). A phase II…”
Get full text

Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer by Saloustros, E, Kalbakis, K, Vardakis, N, Kalykaki, A, Milaki, G, Rovithi, M, Agelaki, S, Saridaki, Z, Georgoulias, V, Mavroudis, D

“…Continuous administration of oral vinorelbine, given 3 times a week (metronomic), is feasible and exceptionally well tolerated at doses up to 50 mg with…”
Get more information